Lansing Street Advisors’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.86M Buy
1,550
+54
+4% +$55.2K 0.39% 47
2026
Q1
$1.38M Sell
1,496
-217
-13% -$220K 0.35% 52
2025
Q4
$1.84M Sell
1,713
-138
-7% -$132K 0.47% 42
2025
Q3
$1.41M Buy
1,851
+58
+3% +$43.2K 0.37% 46
2025
Q2
$1.4M Buy
1,793
+349
+24% +$271K 0.42% 43
2025
Q1
$1.19M Buy
1,444
+132
+10% +$110K 0.4% 42
2024
Q4
$1.01M Buy
1,312
+664
+102% +$550K 0.35% 44
2024
Q3
$575K Buy
648
+21
+3% +$18.9K 0.21% 60
2024
Q2
$568K Buy
627
+41
+7% +$32.8K 0.24% 61
2024
Q1
$456K Sell
586
-29
-5% -$20.6K 0.21% 64
2023
Q4
$358K Buy
+615
New +$359K 0.19% 62
2023
Q2
$301K Buy
643
+1
+0.2% +$419 0.17% 64
2023
Q1
$220K Buy
642
+1
+0.2% +$337 0.14% 75
2022
Q4
$234K Buy
641
+8
+1% +$2.84K 0.16% 77
2022
Q3
$205K Hold
633
0.16% 78
2022
Q2
$205K Buy
633
+1
+0.2% +$300 0.16% 76
2022
Q1
$197K Buy
+632
New +$163K 0.13% 81

Other funds holding LLY

Lansing Street Advisors's LLY Position: Q2 2026 in Review

Lansing Street Advisors increased its Eli Lilly (LLY) stake by 3.6% in Q2 2026, buying an estimated $55.2K and bringing the position to 1,550 shares worth $1.86M. The position accounts for 0.39% of the portfolio, ranked #47.

Lansing Street Advisors first reported a position in LLY in Q1 2022 and has held it in 17 quarters since. 2,000 funds tracked by Wall St. Rank hold LLY as of Q2 2026.

  • Lansing Street Advisors held 1,550 shares of Eli Lilly worth $1.86M as of Q2 2026.
  • Lansing Street Advisors bought 54 Eli Lilly shares in Q2 2026, an estimated $55.2K.
  • Eli Lilly made up 0.39% of Lansing Street Advisors's portfolio in Q2 2026, its #47 holding.
  • Lansing Street Advisors first reported a position in Eli Lilly in Q1 2022 and has held it in 17 quarters since.
  • 2,000 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.

Based on Lansing Street Advisors's 13F filing for Q2 2026, filed 24 Jul 2026.